Contributors

Jean M. Abraham
Division of Health Policy and Management
University of Minnesota
420 Delaware Street SE, MMC 729
Minneapolis, MN 55455

Murray L. Aitken
IMS Institute for Healthcare Informatics
901 Main Avenue, Suite 612
Norwalk, CT 06851

Ana Aizcorbe
Bureau of Economic Analysis
4600 Silver Hill Road
Suitland, MD 20746

Colin Baker
US Department of Health and Human Services
200 Independence Avenue SW
Washington, DC 20201

Laurence C. Baker
Department of Health Research & Policy
HRP Redwood Building
Stanford University
Stanford, CA 94305-5405

Didem Bernard
Agency for Healthcare Research and Quality
Center for Financing, Access, and Cost Trends
540 Gaither Road
Rockville, MD 20850

Ernst R. Berndt
MIT Sloan School of Management
100 Main Street, E62-518
Cambridge, MA 02142

Barry Bosworth
The Brookings Institution
1775 Massachusetts Avenue
Washington, DC 20036

Ralph Bradley
Division of Price and Index Number Research
Bureau of Labor Statistics
2 Massachusetts Avenue, NE
Washington, DC 20212

M. Kate Bundorf
Health Research and Policy
Stanford University
HRP T108
Stanford, CA 94305-5405
Brian Chansky  
Bureau of Labor Statistics  
Division of Industry Productivity Studies  
2 Massachusetts Avenue, NE  
Washington, DC 20212

Richard Frank  
Department of Health Care Policy  
Harvard Medical School  
180 Longwood Avenue  
Boston, MA 02115

Corby Garner  
Bureau of Labor Statistics  
2 Massachusetts Avenue, NE  
Washington, DC 20212

Kaushik Ghosh  
National Bureau of Economic Research  
1050 Massachusetts Avenue  
Cambridge, MA 02138

Jacob Glazer  
Department of Economics  
Warwick University  
Coventry CV4 7AL United Kingdom  
and Coller School of Management  
Tel Aviv University  
Ramat Aviv, Tel Aviv, Israel

Dana P. Goldman  
Schaeffer Center for Health Policy and Economics  
University of Southern California  
635 Downey Way  
Los Angeles, CA 90089-3333

Anne E. Hall  
Office of Microeconomic Analysis  
US Treasury Department  
1500 Pennsylvania Avenue, NW  
Washington, DC 20220

Tina Highfill  
Bureau of Economic Analysis  
4600 Silver Hill Road  
Suitland, MD 20746

Pinar Karaca-Mandic  
Division of Health Policy and Management  
University of Minnesota  
420 Delaware Street SE, MMC 729  
Minneapolis, MN 55455

Abe Dunn  
Bureau of Economic Analysis  
4600 Silver Hill Road  
Suitland, MD 20746

Roger Feldman  
Division of Health Policy and Management  
University of Minnesota  
420 Delaware Street SE, MMC 729  
Minneapolis, MN 55455

Armando Franco  
Department of Economics  
University of California, Berkeley  
Berkeley, CA 94720
Contributors

Michael Kleinrock
QuintilesIMS Institute
QuintilesIMS
One IMS Drive
Plymouth Meeting, PA 19462

J. Steven Landefeld
Economics Department
US Naval Academy
589 McNair Road
Annapolis, MD 21402-5030

Adam Leive
Frank Batten School of Leadership and Public Policy
University of Virginia
235 McCormick Road
Charlottesville, VA 22904

Frank R. Lichtenberg
Graduate School of Business
Columbia University
3022 Broadway
New York, NY 10027

Eli Liebman
Bureau of Economic Analysis
4600 Silver Hill Road
Suitland, MD 20746

Matilde Mas
Faculty of Economics
Universitat de València
Edifici Departamental Oriental
Avda. Tarongers, s/n.
46022 Valencia, Spain

Daniel McFadden
University of California, Berkeley
Department of Economics
508-1 Evans Hall #3880
Berkeley, CA 94720-3880

Thomas G. McGuire
Department of Health Care Policy
Harvard Medical School
180 Longwood Avenue
Boston, MA 02115

Yuriy Pylypchuk
Office of the National Coordinator for Health Information Technology
330 C Street, SW
Washington, DC 20024

Ronjoy Raichoudhary
Bureau of Labor Statistics
2 Massachusetts Avenue, NE
Washington, DC 20212

Allison B. Rosen
Department of Quantitative Health Sciences
University of Massachusetts Medical School
368 Plantation Street, AS9-1083
Worcester, MA 01605

Anne Royalty
Department of Economics
Indiana University Purdue University
Indianapolis
425 University Boulevard
Indianapolis, IN 46202

Paul Schreyer
Organisation for Economic Co-Operation and Development
2, rue André Pascal
75775 Paris Cedex 16 France

Thomas Selden
Agency for Healthcare Research and Quality
Center for Financing, Access, and Cost Trends
540 Gaither Road
Rockville, MD 20850

Bradley T. Shapiro
University of Chicago Booth School of Business
5807 South Woodlawn Avenue
Chicago, IL 60637

Adam Hale Shapiro
Economic Research Department
Federal Reserve Bank of San Francisco
101 Market Street
San Francisco, CA 94105
Julie Shi
School of Economics
Peking University
5 Yiheyuan Road
Haidian District
Beijing 100871 China

Christopher Stomberg
Bates White Economic Consulting
1300 Eye Street NW
Suite 600
Washington, DC 20005

Kosali Simon
School of Public and Environmental Affairs
Indiana University
1315 East Tenth Street
Bloomington, IN 47405-1701
Author Index

Abaluck, J., 385n10
Abraham, J. M., 421, 422, 424, 426n8, 427, 428, 428n10, 442, 443, 444
Abraham, K. G., 27
Adams, J. D., 477
Aitken, M. L., 244n1, 244n4, 247n13, 250n14, 253, 274, 276, 284, 285n1, 306
Aizcorbe, A., 82, 85, 99n21, 111, 115, 118, 119, 157, 174, 181, 201, 391
Akerlof, G. A., 380n3
Akobundu, E., 201
Akscin, J., 281
Allison, E., 461
Alpert, A., 245n10, 280, 283
Amemiya, T., 231
Antwi, Y. A., 352
Appelt, S., 244n7, 245n9
Atkinson, A., 27, 37, 44
Auerbach, D. I., 357

Baker, C., 236, 236n20
Baker, L. C., 82, 84, 95, 98, 352
Balk, B., 35n7
Barr, T. R., 280, 281
Basu, A., 71n5, 186, 188, 202
Berenson, R. A., 351, 352
Berk, A., 174, 177
Bernard, D. M., 462n3, 463, 471
Berndt, E. R., 27, 31, 32, 32n5, 36, 81, 115, 244n1, 244n2, 244n4, 244n7, 245n9, 246n11, 247n13, 250n14, 253, 253n16, 256n19, 274, 276, 285, 285n1, 306, 307, 323, 328n7
Berry, S., 282, 283, 306
Bhat, S., 336n27
Bhattacharya, J., 212, 214n5, 214n7, 217n12, 218n15, 462n3
Bloom, B. S., 174
Blumberg, L., 443
Bond, A. M., 351
Bosworth, B. P., 27
Boudreaux, M., 421, 422
Bradley, R., 174, 201, 218n15
Branstetter, L. G., 244n7, 245n9
Bresnahan, T. F., 282, 284
Brill, A., 244n6, 251
Buchanan, J., 76
Buchmueller, T., 443
Buerhaus, P. I., 357
Bundorf, M. Kate, 82, 84, 95, 98, 214n5, 214n7, 382, 384n8, 386
Buntin, M. B., 116, 186, 188, 202
Burton, T., 59
Cantor, J. C., 422
Carlin, C., 386
Carter, G., 382
Casalino, L. P., 353, 353n1, 354
Castelli, A., 47
Catron, B., 167
Caves, R. E., 244n2, 244n4, 253n16, 274, 283, 284, 285, 307
<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cawley, J.</td>
<td>211, 212, 213, 214, 219, 220, 234, 235</td>
</tr>
<tr>
<td>Chandra, A.</td>
<td>66</td>
</tr>
<tr>
<td>Chang, L. V.</td>
<td>244n6, 252</td>
</tr>
<tr>
<td>Chatterjee, C.</td>
<td>244n7, 245n9</td>
</tr>
<tr>
<td>Chernew, M.</td>
<td>81</td>
</tr>
<tr>
<td>Claxton, G.</td>
<td>447</td>
</tr>
<tr>
<td>Clemens, J.</td>
<td>280</td>
</tr>
<tr>
<td>Cockburn, I. M.</td>
<td>244n2, 250n14, 253n16, 284, 306</td>
</tr>
<tr>
<td>Cohen, A. J.</td>
<td>174, 177, 194</td>
</tr>
<tr>
<td>Cohen, S. B.</td>
<td>462</td>
</tr>
<tr>
<td>Conti, R. M.</td>
<td>274, 277, 281, 285, 290, 306, 323, 328n7</td>
</tr>
<tr>
<td>Cook, A.</td>
<td>244n2, 244n3, 250n14, 253n16</td>
</tr>
<tr>
<td>Cooper, B. S.</td>
<td>174, 194</td>
</tr>
<tr>
<td>Coultts, E.</td>
<td>463</td>
</tr>
<tr>
<td>Cox, C.</td>
<td>447</td>
</tr>
<tr>
<td>Crosson, F. J.</td>
<td>352</td>
</tr>
<tr>
<td>Cuckler, G. A.</td>
<td>459</td>
</tr>
<tr>
<td>Cuellar, A. E.</td>
<td>352</td>
</tr>
<tr>
<td>Cullen, M.</td>
<td>380n2, 382, 383, 384, 384n6</td>
</tr>
<tr>
<td>Cutler, D. M.</td>
<td>27, 84, 105, 115, 158, 173, 174, 181, 201, 212, 213, 215, 244n1, 244n4, 250n14, 253, 274, 306, 380n3, 396n25, 475</td>
</tr>
<tr>
<td>Cylus, J.</td>
<td>158</td>
</tr>
<tr>
<td>Dafny, L.</td>
<td>352, 386, 426n8</td>
</tr>
<tr>
<td>Dahlof, B.</td>
<td>56</td>
</tr>
<tr>
<td>Davidoff, A.</td>
<td>443</td>
</tr>
<tr>
<td>Deaton, A.</td>
<td>475</td>
</tr>
<tr>
<td>DeLeire, T.</td>
<td>424</td>
</tr>
<tr>
<td>Devlin, J. W.</td>
<td>336n27</td>
</tr>
<tr>
<td>Dickensheets, B.</td>
<td>158</td>
</tr>
<tr>
<td>Diewert, W. E.</td>
<td>33, 35n7</td>
</tr>
<tr>
<td>DiNardo, J.</td>
<td>443</td>
</tr>
<tr>
<td>Dominik, L.</td>
<td>82, 85, 174</td>
</tr>
<tr>
<td>Dorfman, R.</td>
<td>331n11</td>
</tr>
<tr>
<td>Douglas, J.</td>
<td>149n10</td>
</tr>
<tr>
<td>Dow, W. H.</td>
<td>220n16</td>
</tr>
<tr>
<td>Dragone, D.</td>
<td>213, 215</td>
</tr>
<tr>
<td>Druss, B. G.</td>
<td>174, 180</td>
</tr>
<tr>
<td>Duan, N.</td>
<td>116, 194</td>
</tr>
<tr>
<td>Duarte, F.</td>
<td>280, 283</td>
</tr>
<tr>
<td>Duchnovy, N.</td>
<td>236, 236n20</td>
</tr>
<tr>
<td>Duggan, M.</td>
<td>245, 285n1</td>
</tr>
<tr>
<td>Dunn, A.</td>
<td>82, 85, 86n2, 87, 91n10, 92n11, 92n12, 94n14, 95, 99n21, 101n24, 101n25, 111, 115, 119, 174, 181, 201, 352</td>
</tr>
<tr>
<td>Earle, C.</td>
<td>281, 285, 306</td>
</tr>
<tr>
<td>Einav, L.</td>
<td>380n2, 382, 383, 384, 384n6, 386</td>
</tr>
<tr>
<td>Elixhauser, A.</td>
<td>192</td>
</tr>
<tr>
<td>Ellis, R. P.</td>
<td>394n22</td>
</tr>
<tr>
<td>Ellison, G.</td>
<td>244n2, 253n16</td>
</tr>
<tr>
<td>Ellison, S. F.</td>
<td>244n2, 250n14, 253n16, 284, 285, 306</td>
</tr>
<tr>
<td>Evenson, R. E.</td>
<td>477</td>
</tr>
<tr>
<td>Feenberg, D.</td>
<td>463</td>
</tr>
<tr>
<td>Feldman, R.</td>
<td>443</td>
</tr>
<tr>
<td>Feldstein, M.</td>
<td>461</td>
</tr>
<tr>
<td>Fiebelkorn, I. C.</td>
<td>211</td>
</tr>
<tr>
<td>Finkelstein, A.</td>
<td>380n2, 382, 383, 384, 384n6, 386</td>
</tr>
<tr>
<td>Finkelstein, E. A.</td>
<td>118, 194, 211</td>
</tr>
<tr>
<td>Fixler, D.</td>
<td>167</td>
</tr>
<tr>
<td>Florence, C. S.</td>
<td>99n21, 174, 180, 194, 211, 235</td>
</tr>
<tr>
<td>Fox, E. R.</td>
<td>335n20, 336n23, 336n26</td>
</tr>
<tr>
<td>Frank, R. G.</td>
<td>244n2, 244n3, 274, 279, 284, 285, 289, 306, 307</td>
</tr>
<tr>
<td>Franklin, S.</td>
<td>56</td>
</tr>
<tr>
<td>Friedman, B.</td>
<td>155</td>
</tr>
<tr>
<td>Fuchs, V. R.</td>
<td>476n1</td>
</tr>
<tr>
<td>Galactionova, K.</td>
<td>174</td>
</tr>
<tr>
<td>Galiani, S.</td>
<td>486n13</td>
</tr>
<tr>
<td>Gatesman, M.</td>
<td>278</td>
</tr>
<tr>
<td>Gaynor, M. S.</td>
<td>306, 351, 352</td>
</tr>
<tr>
<td>Gertler, P. J.</td>
<td>352, 486n13</td>
</tr>
<tr>
<td>Geruso, M.</td>
<td>386</td>
</tr>
<tr>
<td>Ginsburg, M.</td>
<td>167</td>
</tr>
<tr>
<td>Ginsburg, P. B.</td>
<td>352</td>
</tr>
<tr>
<td>Glaser, E. M.</td>
<td>212, 213, 215</td>
</tr>
<tr>
<td>Glazer, J.</td>
<td>380n3, 382, 384n8</td>
</tr>
<tr>
<td>Goerlich, F.</td>
<td>42</td>
</tr>
<tr>
<td>Gold, M. R.</td>
<td>37</td>
</tr>
<tr>
<td>Goldberg, P.</td>
<td>278</td>
</tr>
<tr>
<td>Goldman, D.</td>
<td>62, 76</td>
</tr>
<tr>
<td>Gornick, M.</td>
<td>75</td>
</tr>
<tr>
<td>Gottlieb, J. D.</td>
<td>280</td>
</tr>
<tr>
<td>Grabowski, H. G.</td>
<td>244n2, 244n5, 244n6, 244n7, 250n14, 253n16, 274, 282, 283, 284, 285, 306, 307</td>
</tr>
<tr>
<td>Graham, J. R.</td>
<td>323</td>
</tr>
<tr>
<td>Graven, P.</td>
<td>443</td>
</tr>
<tr>
<td>Gray, B. M.</td>
<td>461</td>
</tr>
<tr>
<td>Griliches, Z.</td>
<td>244n2, 250n14, 253n16, 284, 306</td>
</tr>
<tr>
<td>Grossman, J. M.</td>
<td>351</td>
</tr>
</tbody>
</table>
Author Index

Growlec, J., 489n15
Gruber, J., 385n10
Gu, W., 42

Hall, A. E., 111, 118, 124n1, 201
Hall, H., 56
Hall, J. M., 446
Hall, M. A., 447n14
Hamilton, B., 75
Handel, B., 386
Haninger, K., 333
Haught, R., 461
Hellerstein, J. K., 245n10
Helms, R. B., 461
Hemphill, C. S., 244n5, 244n7
Hendel, I., 386
Henderson, R., 145
Higgins, M. J., 244n7, 245n9
Highfill, T., 111, 118, 124n1, 201
Hill, T. P., 27, 30
Ho, K., 386
Hodgson, T. A., 174, 177, 194
Hoerger, T. H., 118, 194
Hoffman, C., 174, 177
Hogan, P., 461
Honeycutt, A. A., 201
Horowitz, L. A., 174
Howard, D. H., 174
Huckfeldt, C. R., 285, 307
Huckman, R. S., 244n6, 256n18
Hurwitz, M. A., 244n2, 244n4, 253n16, 274, 283, 284, 285, 307
Huskamp, H. A., 253n16
Hüttl, A., 42

Iizuka, T., 276, 282, 283, 287, 289, 305
Jacobson, M., 280, 281, 283, 285, 306
Jessup, A., 333
Jones, A. M., 116
Jordan, W. M., 280
Jorgenson, D. W., 28, 29
Joski, P., 99n21, 174, 180, 194, 211, 235
Joyce, G., 62

Karaca-Mandic, P., 421, 422, 424, 426n8, 427, 428, 428n10, 442, 443, 444
Keeler, E., 382
Kelton, C. M., 244n6, 252
Kerwin, J., 184
Kessler, D. P., 364
Ketcham, J. D., 352
Kislev, Y., 477
Klerman, J. A., 422
Knittel, P. J., 285, 307
Kocher, R., 351
Koechlin, F., 30, 43, 46, 46n2
Koehler, M. A., 333
Kolstad, J. T., 306, 384n6
Koopmanschap, M. A., 174
Kopstein, A. N., 174, 177
Kornfield, R., 307
Kowalski, A., 384n6
Kreling, D. H., 244n6, 252
Kyle, M. K., 244n2, 244n5, 274, 282, 285, 307

Lakdawalla, D., 462n3
Landefeld, J. S., 28
Lane, S. G., 158n24
Leibowitz, A., 76
Levin, J. D., 380, 384n8, 386, 417
Levitt, L., 447
Li, Y., 56
Lichtenberg, F. R., 476, 489, 495n20
Liebman, E., 82, 85, 86n2, 95, 99n21, 101n24, 101n25, 174, 181, 201, 309, 323, 330, 330n9, 333
Lieberman, A., 351
Lincoln, G., 396n25
Ling, D., 274, 285, 307
Lipscomb, J., 201
Liu, X., 446
Lleras-Muney, A., 475
Long, G., 244n2, 244n6, 307
Long, S., 443
Lorenzoni, L., 30, 43, 46, 46n2
Lucarelli, C., 386
Lustig, J., 386

Mach, A., 422
MacIsaac, D., 352
Mackie, C., 27
Macurdy, T., 184
Maddala, G. S., 219
Mahoney, N., 382, 384n8, 386
Malin, J. L., 281
Maness, R., 244n2, 244n3, 274, 283, 284, 285, 287, 305
Mankiw, N. G., 282, 306
Manning, W. G., 116, 186, 188, 202
Marquis, M. S., 443
<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martin, A. B.</td>
<td>459</td>
</tr>
<tr>
<td>Martin, J. B.</td>
<td>475</td>
</tr>
<tr>
<td>Mas, 29</td>
<td></td>
</tr>
<tr>
<td>Matchar, D.</td>
<td>61</td>
</tr>
<tr>
<td>McClellan, M. B.</td>
<td>364, 462</td>
</tr>
<tr>
<td>McCue, M. J.</td>
<td>446, 447n14</td>
</tr>
<tr>
<td>McGlynn, E. A.</td>
<td>184</td>
</tr>
<tr>
<td>McGuire, T. G.</td>
<td>380n3, 382, 384n8, 393n20</td>
</tr>
<tr>
<td>McWilliams, J. M.</td>
<td>352, 356</td>
</tr>
<tr>
<td>Meeker, D.</td>
<td>76</td>
</tr>
<tr>
<td>Melnick, G. A.</td>
<td>352</td>
</tr>
<tr>
<td>Meyerhofer, C.</td>
<td>211, 212, 213, 214, 219, 220, 234, 235</td>
</tr>
<tr>
<td>Miller, G. E.</td>
<td>461, 471</td>
</tr>
<tr>
<td>Moeller, J. F.</td>
<td>460</td>
</tr>
<tr>
<td>Moffitt, R.</td>
<td>462n3</td>
</tr>
<tr>
<td>Monheit, A.</td>
<td>424, 456</td>
</tr>
<tr>
<td>Morin, S.</td>
<td>42</td>
</tr>
<tr>
<td>Mortimer, R.</td>
<td>244n2, 244n6, 307</td>
</tr>
<tr>
<td>Moses, H.</td>
<td>475</td>
</tr>
<tr>
<td>Mullahy, J.</td>
<td>116, 186, 202</td>
</tr>
<tr>
<td>Murphy, B.</td>
<td>167</td>
</tr>
<tr>
<td>Mushkin, S. J.</td>
<td>174, 177</td>
</tr>
<tr>
<td>Nabel, E. G.</td>
<td>475</td>
</tr>
<tr>
<td>Nakamura, A.</td>
<td>35n7</td>
</tr>
<tr>
<td>Nestoriak, N.</td>
<td>82, 99n21, 111, 115, 119, 157, 174, 181, 201</td>
</tr>
<tr>
<td>Neumann, P. J.</td>
<td>280</td>
</tr>
<tr>
<td>Newey, W. K.</td>
<td>212</td>
</tr>
<tr>
<td>Newhouse, J. P.</td>
<td>81, 250n14, 256n19, 276, 281, 285, 306, 382, 400n27</td>
</tr>
<tr>
<td>Nichols, L.</td>
<td>443</td>
</tr>
<tr>
<td>Norton, E. C.</td>
<td>220n16</td>
</tr>
<tr>
<td>Ogden, L. L.</td>
<td>174</td>
</tr>
<tr>
<td>O’Hara, B.</td>
<td>422</td>
</tr>
<tr>
<td>Olin, G.</td>
<td>85, 121, 391</td>
</tr>
<tr>
<td>Olson, L. M.</td>
<td>244n7, 245n9, 260n23</td>
</tr>
<tr>
<td>O’Malley, A. S.</td>
<td>351</td>
</tr>
<tr>
<td>Pack, S.</td>
<td>174, 181, 201</td>
</tr>
<tr>
<td>Palmer, L.</td>
<td>192</td>
</tr>
<tr>
<td>Panattoni, L. E.</td>
<td>244n7, 304</td>
</tr>
<tr>
<td>Paringer, L.</td>
<td>174, 177</td>
</tr>
<tr>
<td>Park, R.</td>
<td>116</td>
</tr>
<tr>
<td>Pauly, M. V.</td>
<td>218n15</td>
</tr>
<tr>
<td>Pelnar, G. J.</td>
<td>354</td>
</tr>
<tr>
<td>Pérez, F.</td>
<td>29</td>
</tr>
<tr>
<td>Pham, H. H.</td>
<td>355</td>
</tr>
<tr>
<td>Phelps, C.</td>
<td>424, 444</td>
</tr>
<tr>
<td>Pindyck, R. S.</td>
<td>281</td>
</tr>
<tr>
<td>Pope, G. C.</td>
<td>355, 394</td>
</tr>
<tr>
<td>Powell, J. L.</td>
<td>212</td>
</tr>
<tr>
<td>Prince, J.</td>
<td>386</td>
</tr>
<tr>
<td>Pylypchuk, Y.</td>
<td>463</td>
</tr>
<tr>
<td>Reber, S.</td>
<td>380n3</td>
</tr>
<tr>
<td>Regan, T. L.</td>
<td>244n3, 253n16</td>
</tr>
<tr>
<td>Reiffen, D. E.</td>
<td>244n2, 245n9, 258n20, 274, 282, 284, 285, 305</td>
</tr>
<tr>
<td>Reiss, P.</td>
<td>282, 283, 284, 306</td>
</tr>
<tr>
<td>Rennane, S.</td>
<td>470</td>
</tr>
<tr>
<td>Retus, B. A.</td>
<td>174, 181, 201</td>
</tr>
<tr>
<td>Rice, D. P.</td>
<td>174, 176, 177, 194</td>
</tr>
<tr>
<td>Ridley, D. B.</td>
<td>309, 323, 330, 330n9, 333</td>
</tr>
<tr>
<td>Rittmueller, L.</td>
<td>174, 181, 201</td>
</tr>
<tr>
<td>Roberts, R.</td>
<td>336n27</td>
</tr>
<tr>
<td>Roehrig, C.</td>
<td>82, 85, 98, 98n20, 99n21, 103n28, 174, 180, 181</td>
</tr>
<tr>
<td>Romer, P.</td>
<td>476</td>
</tr>
<tr>
<td>Rosen, A. B.</td>
<td>27, 92n11, 158, 174, 184, 201</td>
</tr>
<tr>
<td>Rothschild, M.</td>
<td>380n3</td>
</tr>
<tr>
<td>Rousseau, D.</td>
<td>82, 85, 98, 98n20, 99n21, 103n28, 174, 180, 181</td>
</tr>
<tr>
<td>Royalty, A. B.</td>
<td>82, 84, 95, 98, 424</td>
</tr>
<tr>
<td>Rubinfeld, D. L.</td>
<td>282</td>
</tr>
<tr>
<td>Ruhm, C. J.</td>
<td>212, 215</td>
</tr>
<tr>
<td>Russo, C. A.</td>
<td>155</td>
</tr>
<tr>
<td>Safar, M.</td>
<td>56</td>
</tr>
<tr>
<td>Saha, A.</td>
<td>244n2</td>
</tr>
<tr>
<td>Sahni, N. R.</td>
<td>173, 351</td>
</tr>
<tr>
<td>Salkever, D. S.</td>
<td>244n2, 244n3, 274, 284, 285, 289, 306, 307</td>
</tr>
<tr>
<td>Sampat, B. N.</td>
<td>244n5, 244n7, 476</td>
</tr>
<tr>
<td>Savorelli, L.</td>
<td>213, 215</td>
</tr>
<tr>
<td>Schargrodsky, E.</td>
<td>486n13</td>
</tr>
<tr>
<td>Scherer, F. M.</td>
<td>306</td>
</tr>
<tr>
<td>Schneider, J. E.</td>
<td>352</td>
</tr>
<tr>
<td>Schone, B. S.</td>
<td>424, 443</td>
</tr>
<tr>
<td>Schreyer, P.</td>
<td>27, 29, 30, 32, 33, 36, 37, 42, 43, 46, 46n2</td>
</tr>
<tr>
<td>Schumacher, I.</td>
<td>489n15</td>
</tr>
<tr>
<td>Schwartz, L. M.</td>
<td>484</td>
</tr>
<tr>
<td>Scitovsky, A. A.</td>
<td>174, 177</td>
</tr>
<tr>
<td>Scott Morton, F. M.</td>
<td>244n2, 244n6, 274, 276, 277, 282, 285, 285n1, 287, 289, 305</td>
</tr>
<tr>
<td>Selden, T. M.</td>
<td>460, 461, 462, 462n3, 463, 471</td>
</tr>
<tr>
<td>Senese, J. L.</td>
<td>280, 281</td>
</tr>
<tr>
<td>Shapiro, A. H.</td>
<td>82, 85, 86n2, 94n14, 95, 99n21, 101n24, 101n25, 174, 181, 201, 375</td>
</tr>
<tr>
<td>Shapiro, I.</td>
<td>115</td>
</tr>
</tbody>
</table>
Shapiro, J. M., 212, 213, 215
Shapiro, M. D., 115
Sheils, J., 461
Shen, Y. C., 352
Simon, K., 386, 426n8, 428, 442, 443
Sing, M., 391, 462, 471
Sipahi, I., 58, 58n2
Skinner, J., 462
Sloan, F. A., 471
Smedby, B., 46n2
Smith, A., 247n13
Smith, S., 174, 181, 201
Smith, T., 278
Song, X., 174, 201
Sood, N., 212, 214n7, 217n12, 218n15
Spinnewijn, J., 385n9
Staiger, D. O., 66, 357
Starr, M., 82, 85, 174
Steiner, C., 192
Steiner, P. O., 331n11
Steuerle, C. E., 470
Stiglitz, J., 380n3
Stranges, E., 155
Strauss, M., 56
Stromberg, C., 309
Sung, H. Y., 174, 177
Theobald, N., 184
Thorpe, K. E., 99n21, 174, 180, 194, 211, 235
Tirole, J., 282
Todd, P., 57
Towler, E. L., 280, 281
Town, R. J., 351, 386
Triplett, J. E., 27, 35n9, 36, 36n10, 37, 47, 154
Trish, E., 391n15
Trogdon, J., 116, 194
Uriel, E., 29
Van de Ven, W. P. M. M., 394n22
Vanoli, A., 33n6

Varela, M., 386
Varmus, H., 484
Vella, F., 213
Vernon, J. M., 244n2, 250n14, 253n16, 274, 282, 283, 284, 285, 306
Vijan, S., 27
Vogt, W., 306, 352

Wang, G., 211
Wang, J., 56, 471
Wang, X., 244n7
Ward, M. E., 244n2, 245n9, 258n20
Ward, M. M., 201
Ward, M. R., 274, 282, 284, 285, 305
Waselenko, M. J., 462
Welch, C. A., 202
Welch, H. G., 484
Welch, W. P., 352, 355, 356, 357
Wendling, B. W., 244n7, 245n9, 260n23
Whinston, M. D., 244n2, 244n4, 253n16, 274, 282, 283, 284, 285, 306, 307, 386
Whitmire, B., 174, 181, 201
Wiggins, S. N., 244n2, 244n3, 274, 283, 284, 285, 287, 305
Wilcox, D. W., 115
Wilson, D., 278
Wolfe, B., 462n3
Woloshin, S., 484
Wolpin, K., 57
Woodcock, J., 278, 323, 328
Wosinska, M., 244n6, 256n18, 278, 323, 328
Wu, V. Y., 352

Yabroff, K. R., 201
Yun, K.-Y., 28
Yurukoglu, A., 308, 323, 330, 330n9, 333
Zaslavsky, A. M., 116, 186, 188, 202
Zeckhauser, R., 396n25
Zhang, H. H., 471
Zhu, J. M., 393n21
Zissimopoulos, J., 62
Zuvekas, S., 85, 121, 391
Subject Index

Note: Page numbers followed by “f” or “t” refer to figures or tables, respectively.

Abbreviated New Drug Applications (ANDAs), 275–76; information and regulatory timing of, 277–78; price and use models of, theoretical considerations, 284–86; theoretical considerations and empirical findings for entry models of, 281–83

ACA. See Affordable Care Act (ACA) of 2010

accounting, health, 1

ACE (angiotensin-converting enzyme) inhibitors, 58

active pharmaceutical ingredients (API), 276

adverse selection: efficiency costs of, 382–84, 383f; “Einav-Finkelstein” form of, 380; risk adjustment and, 379–80; risk adjustment to fix, 386–90

Affordable Care Act (ACA) of 2010, 17–20, 379, 382, 386, 419–21; plan levels in, 382, 393

AHA (American Hospital Association) Annual Survey, 150, 150n15, 165

all-encounter approach, to COI allocation, 176, 194; literature review using, 180–81, 182–83t

Ambien CR, 266–67

American Hospital Association (AHA) Annual Survey, 150, 150n15, 165

ANDAs. See Abbreviated New Drug Applications (ANDAs)

angiotensin-converting enzyme (ACE) inhibitors, 58

angiotensin II receptor blockers (ARBs), 4, 56–57, 58; cancer rates and propensity to prescribe, 66–69, 67f, 72–73, 73t; contamination bias and analysis of, 60–63; death rates and propensity to prescribe, 66–69, 67f; empirical sequencing of use for users of, 62, 63f; instrumental variables regressions for, 70–73, 71t; physician propensity to prescribe, 66; relationship between relative price and use of, 72, 72f; robustness checks for analysis of, 73–75; sample selection for analyzing issues of, 59–60; simulations of reducing prescriber propensity for, 68t, 69; unconditional relationship between pain rate and propensity to prescribe, 69–70, 69f. See also hypertension drug treatments

API (active pharmaceutical ingredients), 276

Atkinson Review, 44

Augmentin XR, 266

Australia, practices in volume measurement of health services in, 38t
Austria, practices in volume measurement of health services in, 38t
authorized generics, 11

Belgium, practices in volume measurement of health services in, 38t
benefit incidence analysis, of public spending on health care, 462–70; ACA-relevant subgroups, 468–70, 469t; age groups, 464–66, 465t; aggregate results, 464, 465t; health status, 466, 467t; insurance coverage, 467t, 468; poverty level, 465t, 466. See also health care

beta blockers, 58
biomedical research, 475; assessing impact of, on cancer mortality, 486–90, 487–88t; kinds of evidence used by, 476; publications data for, 477–84; US spending on, 480–81, 481f

BLS (Bureau of Labor Statistics) Industry Employment and Hours data, 149, 167
body mass index (BMI), 8–10, 211
brand name drugs, 275
calcium channel blockers, 58
Canada, practices in volume measurement of health services in, 38t
cancer, 4, 56–57, 477; ARBs and, 56–58; assessing impact of biomedical research on mortality of, 486–90, 487–88t; correlation between sites of, between FY 2009 NIH funding and US government funded research publications, 482, 482f; descriptive statistics for incidence and mortality rates of, 490–94; econometric model of mortality rates of, 484–90; estimates of models of 1995–2009 growth of age-adjusted mortality rate of, 494–99, 501–2t; mortality rates of, 484–86; statistics used to assess progress in war on, 484; survival rates of, 484–85; types of statistics used to assess progress in war on, 484
cancer incidence rate, defined, 477n2
cancer medications, 12
cardiology, disease-specific indexes for, 103–5, 104t
case types, 46
Center for Devices and Radiological Health (CDRH), 338
Center for Drug Evaluation and Research (CDER), 338–40
CER. See comparative effectiveness research (CER)
CMS Statistical Supplement, 150, 166–67
COI. See cost-of-illness (COI) approaches; cost-of-illness (COI) studies
commercial episode groupers, 184
commercial grouper method, for MCEs, 119
commercial health care market, 82
comparative effectiveness research (CER), 3–4; about, 55; challenges to using observational data for, 63–64; conducting, 56
comparative price levels (CPLs), 47, 48t; for health services, across countries, 48t
conditions, medical: prevalence of, 123–29; ways of partitioning medical spending to, 7
Consumer Price Index (CPI), medical services part of, 31
copayment incentive schemes, 255–56
cost-of-illness (COI) approaches: all-encounter, 176; person level, 175–76; primary-encounter, 176
cost-of-illness (COI) studies, 174; disease-based, 174; general, 174–75; literature review using all-encounter approach, 180–81, 182–83t; literature review using episode approach, 181–84; literature review using person-based approach, 184–86, 187t; literature review using person-based approach, methodological issues, 189–90t; literature review using primary-encounter approach, 176–77; literature review using primary-encounter method, 178–79t
costs, medical. See health care costs
course of treatment model, 6, 7, 148
course of treatment model, of hospital output, 154–55
Cozaar, 266
CPI. See Consumer Price Index (CPI)
CPLs. See comparative price levels (CPLs)
Current Good Manufacturing Practice for Finished Pharmaceuticals (CGMP), 340
Czech Republic, practices in volume measurement of health services in, 38t
data sets, for calculating MCEs, 91–96, 119–29, 163–67; issues of treating prevalence of medical conditions in, 123–29; Medical Current Beneficiary Survey (MCBS), 119–21; Medical Expenditure Panel Survey (MEPS), 120t, 121–23; Medicare claims, 120t, 121; Medicare Current Beneficiary Survey (MCBS), 120t
Denmark, practices in volume measurement of health services in, 38t
diagnosis-related groups (DRGs), 6, 164n28, 170
disease-specific indexes, 103–9, 174; cardiology, 103–5, 104t; endocrinology, 103–5, 104t; gastroenterology, 105, 106t; gynecology, 105–7, 108t; neoplasms, 107, 109. See also medical care expenditure indexes (MCEs)
diuretics, 58
DRGs. See diagnosis-related groups (DRGs)
drugs. See brand name drugs; generic pharmaceuticals; infused/injected drugs; injectable drugs, shortages of; loss of exclusivity (LOE); noninjectable drugs, shortages of; specialty drugs
drug shortages, 323–24; age of unresolved, 325; causes of, 13–14; data used for study of, 335–38; generic drugs and, 13; information on FDA regulatory activity for study of, 338–42; institutional character of US generic market and, 328–30; modeling and analysis for, 342–45; patterns in average, 323–25, 324f; predicting, as result of LOE, 301–3; prices and, 333–34; regression models of, 346–47; regulatory involvement and, 330–33; for selected noninjectable, 326–27, 326t; starts, 325f
Einav-Finkelstein (EF) model, of adverse selection, 380; literature review of, 382–86
employer-sponsored insurance, data and study sample, 188–92
encounter-based allocations, 194
encounter-level costing, 174–75
endocrinology, disease-specific indexes for, 103–5, 104t
episode-based approach, to COI allocation, 181–82
ETG Symmetry grouper, 92, 92n12
European System of Accounts (ESA 1995), economic significance of prices and, 28–29
exclusivity, loss of. See loss of exclusivity (LOE)
extended units (EUs) per prescriptions, 255–56
fee-for-service (FFS) Medicare, 114, 124
Finland, practices in volume measurement of health services in, 38t
France, practices in volume measurement of health services in, 39t
gastroenterology, disease-specific indexes for, 105, 106t
general COI studies, 174–75
Generic Drug User Fee Act, 332
generic pharmaceuticals, 275; authorized, 11; cancer medications and, 12; causes of, 13–14; findings on characteristics of six initial launches of, 247–48, 249t; loss of patient exclusivity and prices of, 12; market share of, conclusions about, 263–66; overall penetration rates of, by payer type and age, 250–53, 251t; penetration rates of, overall and by payer type and age, 11, 250–53, 251t; quantities post-LOE relative to pre-LOE, 253–55, 254t; results of study of, 248–50; shortages and, 13. See also loss of exclusivity (LOE); specialty drugs
Germany, practices in volume measurement of health services in, 39t
Greece, practices in volume measurement of health services in, 39t
Hatch-Waxman Act, 244
health accounting, 1
health care costs: current state of, 2; data issues concerning, 3; econometric approach for modeling, 175; growth in, 173; health benefits and, 21; industrial organization of medical care and, 15–16; obesity and (see obesity); results of study sample of diseases, 195–200; valuing nonmarket activities, 2–3

health care expenditures. See medical care expenditures

health care sector, measuring inflation in, 113

health insurance markets, 16

health services: comparisons of price levels and volumes of, 43–49; domestic demand for, 25; history of measuring, 27; over of country practices in volume measurement of, 37–43, 38–41t; variations in domestic demand for, in OECD countries, 25–27, 27f; volume measurement of, 30–31

Herfindahl-Hirschman Indexes (HHIs), 16, 361–70; for individual markets, 2010, 439f; for individual markets, 2012, 440f; for individual/small group markets, 18–19; for small group markets, 2010, 440f

hospital industry: changes in, 146; characteristics of, that present challenges of measuring output of, 158–59; creating output index for, 146–49; as sector in US economy, 145. See also private hospitals

hospital outputs: course of treatment model of, 151–54; course of treatment model of, results for, 159–61, 160f; data sources for creating models of, 149–51, 151t; ideal measure of, 148–49; primary methods of measuring, 149; procedures model of, 155–57; procedures model of, results for, 161; revenue model of, 157–59; revenue model of, results for, 162; review of course of treatment model of, 154–55. See also outcomes; private hospitals

hospital services: defining, based on outcome of treatment, 148; inpatient, 147–48, 147f; outpatient, 147, 147f

hypertension: adherence of initial treatment by drug class for, 60–61, 61t; ARBs and, 56; defined, 57–58; drug classes, 58; drugs used for treating, 58. See also angiotensin II receptor blockers (ARBs)

hypertension drug treatments: incident cases, 60; incident cases, descriptive statistics for, 63, 65t; left censoring and, 60; prevalent cases, 59–60; prevalent cases, descriptive statistics for, 63, 64t. See also angiotensin II receptor blockers (ARBs)

Iceland, practices in volume measurement of health services in, 39t

incremental cost, of health plans, 382

indexes. See medical care expenditure indexes (MCEs)

individual markets: distribution of premiums in, 449f; enrollment and market share by type of insurer in, 432–33; entry and exit of insurers in, 2010–2012, 438t; evaluating insurer performance prior to 2010 in, 442–44; evaluating insurer performance 2010 and after in, 444–53; HHI for, 2010, 439f; HHI for, 2012, 440f; MLRs for fully credible insurers in, 2010–2012, 451t; number of insurers selling comprehensive health insurance in, 430–31t; performance of insurers in, for health insurance, 442–53; premiums and claims in, 447f; size of, 421–24; structure of, for health insurance, 425–27; structure of, for health insurance, in 2010 and after, 428–42; structure of, for health insurance, prior to 2010, 427–28. See also small group markets

individual/small group markets, 18–19; coverage information and estimates by survey, 2009, 423t; size of, 421–25

industrial organization (IO), of medical care, medical costs and, 15–16

inflation, in health care sector, measuring, 113

infused/injected drugs: barriers to entry for manufacturing, 276; manufacturers of, as contract manufacturers, 276–77; manufacturing technology for, 276

injectable drugs, shortages of, 12–13; empirical analyses of, 14–15

inpatient index, adjusting, for survival rates, 170–72
inpatient services, 147–48, 147f
insurance coverage, population distribution of, in US, 188, 191f. See also employer-sponsored insurance
insurance market structure: in 2010 and after, 428–42; prior to 2010, 427–28
International Classification of Diseases, Ninth Revision, Clinical Modifications (ICD-9-CM), 150, 150n16
Ireland, practices in volume measurement of health services in, 39t
Italy, practices in volume measurement of health services in, 39t
Japan, practices in volume measurement of health services in, 39t
knowledge, counts of publications as indicators of, 477
Korea, practices in volume measurement of health services in, 39t
labor productivity, hospital, 159, 160f
left censoring, 60
Lexapro, 267–68
Lipitor, 267
loss of exclusivity (LOE), of prescription drugs, 12, 243–45, 273–74; data and methodology for analyses of, 246–47; findings of analyses of, 245–46; policy implications of, 304–10; predicting shortages as a result, results of, 301–3; quantities post-relative to pre-, 253–55, 254t; results of count models for, 290–94; results of impact of, on utilization volume, 298–301; results of supplier prices following, 294–98; robustness of findings for, 304. See also generic pharmaceuticals; specialty drugs
Luxembourg, practices in volume measurement of health services in, 40t
MarketScan database, 91, 188; variables in, 193t
MCEs. See medical care expenditure indexes (MCEs)
medical care. See health care
medical care costs. See health care costs
medical care expenditure indexes (MCEs), 4–6, 115; central problem in creation of, 116; commercial grouper software for, 119; comparison of, based on calculations from different data sets, 137–39; comparisons of different methods for calculating, 130–37; data sets for calculating (see data sets, for calculating MCEs); effect of adjustment to growth rate on, for all Medicare beneficiaries, 129, 129t; methodology of construction of, 85–90; primary diagnosis method for, 118–19; regression-based method for, 116–18; results of study of, 96–109. See also disease-specific indexes
medical care expenditures: aggregated indexes for, 96–98; data sources for, 91–96; disease-specific indexes, 103–9; domestic, as percentage of GDP, 26–27, 27f; largest contributors to growth in, 83–85; major practice categories for, 98–103, 100t; methodology of index construction for, 85–91; sources of, 83; three largest contributors to growth in, 83–84; total, equation for, 123; in US, 81, 459
medical care spending, decomposition of, 5
Medical Expenditure Panel Study (MEPS), 9, 17, 18, 20, 121–23, 390, 462–64; constructing outpatient index and, 167–70; critique of, 168–69; prevalence by year in, 127–28t; for study of obesity, 220–21; treated prevalence in, 126–29, 127–28t. See also medical care expenditure indexes (MCEs)
Medical Expenditure Panel Survey (MEPS), Household Component of, 114
medical innovation, benefits of, 21
medical loss ratios (MLRs) regulations, 420–21
medical research. See biomedical research
Medical Subject Headings (MeSH), 478, 479n4
Medicare claims data, 354–55
Medicare Current Beneficiary Survey (MCBS), 11, 119–21; treated prevalence in, 123–26, 125t. See also medical care expenditure indexes (MCEs)
Medicare program, 114; data sets for, 114
Medline, 478
MEPS. See Medical Expenditure Panel Study (MEPS)
MLRs. See medical loss ratios (MLRs)
mortality rates, 484–86. See also cancer
National Hospital Ambulatory Medical Care Survey (NHAMCS), 150, 165–66
National Prescription Audit (NPA) data, 246
National Provider Identifiers (NPIs), 356–57, 358t
National Sales Perspectives (NSP) data, 286
Nationwide Inpatient Sample (NIS), 149–51, 150n13, 163–65, 164n27
neoplasms, disease-specific indexes for, 107, 109
Netherlands, practices in volume measurement of health services in, 40t
New Zealand, practices in volume measurement of health services in, 40t
ninety-day prescriptions, 255–56
NIS (Nationwide Inpatient Sample). See Nationwide Inpatient Sample (NIS)
noninjectable drugs, shortages of, 12–13; empirical analyses of, 14–15
nonmarket activities, valuing, 2–3
Norway, practices in volume measurement of health services in, 41t
NPA (National Prescription Audit) data, 246
NPIs (National Provider Identifiers), 356–57, 358t
NSP (National Sales Perspectives) data, 286
obesity: data used for study of, 220–24; estimating equations for, 224–26; explaining, through use of behavioral economics, 212; health care costs and, 211–12; life-expectancy loss and, 211; rates of, 212; results of study of, 226–34; simple micromodel of, 215–20; simulations for, 234–36; studies of, 8; study of, explained, 212–15; summary statistics for study of, 221–24, 223–24t; US rate of, 221, 221f
observation data, challenges to using, for CER, 63–66
OECD countries. See Organisation for Economic Co-operation and Development (OECD) countries
180-day triopolies, 259–60
optimal risk adjustment, 16–17
Organisation for Economic Co-operation and Development (OECD) countries: overview of practices in, 37–43, 38–41f; variations in domestic demand for health services in, 25–27, 27f
outcomes: meanings of, 37; volume measurement of health services and, 31–33
outpatient services, 147, 147f
outputs, volume measurement of health services and, 31–33. See also hospital outputs
patient exclusivity, loss of, specialty markets and, 12
person approach, to COI allocation, 176, 194–95; estimation techniques in, 186–88; literature review using, 184–86, 187t
person-based allocations, 194–95
person-level costing, 175
pharmaceutical markets: generic drugs and, 11; prescription, 10–15; special markets and, 11–12; specialty drugs and, 11–12
physician market structure, understanding impact of changes in, 352
physician practices: about, 351–53; area-level analyses of, 369–70; concentration measures for (see Herfindahl-Hirschman Indexes [HHIs]); identifying, with TINs, 355–56; Medicare claims data for, 354–55; methods of organizing, 353–54; SK&A (consulting firm) data for, 370–74; studying concentration of, with HHIs, 361–69; trends in number and size of, 358–60, 361t
physicians: identifying, with NPIs, 356–57, 358t; percentage of, seeing Medicare patients, 357
Plavix, 268
Portugal, practices in volume measurement of health services in, 41t

You are reading copyrighted material published by University of Chicago Press.
Unauthorized posting, copying, or distributing of this work except as permitted under U.S. copyright law is illegal and injures the author and publisher.
prescription drugs: cash vs. full sample average price levels and growth rates of, 261–63; extending, to ninety-days, 255–56; findings of LOE and, 245–46; loss of exclusivity (LOE) and, 243–45; price per day of therapy by payer type, 256–59; prices and prescription shares during 180-day triopoly, 259–60; prices per day of therapy by payer type, 257; shortages and, 278; supply and demand side prices of, 278–81; types of, 275 price per day of therapy by payer type, 256–59, 257f
primary diagnosis method, for MCEs, 118–19
primary-encounter approach, to COI allocation, 176; literature review, 176–77, 178–79t
private hospitals, 146; labor productivity in, 159, 160f, 161f; measuring out and productivity growth in, 6–7; output for, 159f. See also hospital outputs
procedures model, of hospital output, 6, 155–57
Producer Price Indexes (PPIs), 6, 151, 167 publications: correlation between major cancers and number of US government-funded, 481–82, 482f; counts of, as indicators of knowledge, 477; distribution of NIH-supported, by lag between start date and publication date, 483–84, 483f
public spending, on medical care, 20–21 PubMed, 477–78, 478n3; abridge sample of bibliographic citations of, 479t; number of publications pertaining to cancer, 478–81, 480f
purchasing power parity (PPP), health-specific, 45–46
Qualified Health Plans (QHPs), 393 quality adjustments, components of, 44–45, 44f quality changes in products, dealing with health services, 35–36 quasi prices, 46–47 randomized controlled trials (RCTs), 55; compared to IV regressions, 75–76; contamination bias and, 60–63 regression-based method, for MCEs, 116–18 revenue model, 6 risk adjustment: adverse selection and, 379–80; empirical application for, 390–98; to fix adverse selection, 386–90; limits of methods for formulas of, 380; results of empirical application for, 398–410 Service Annual Survey (SAS), 151 SHCE (Supplemental Health Care Exhibit), 427, 453 shortages. See drug shortages; injectable drugs, shortages of; noninjectable drugs, shortages of shortages, of injectable and noninjectable drugs, 12–13; empirical analysis of, 14–15 SK&A (consulting firm) data, for physician practices, 370–74 Small Business Health Options Program (SHOP) exchanges, 419–20, 420n2 small group markets: distribution of premiums in, 449f; enrollment and market share by type of insurers in, 436–37t; entry and exit of insurers in, 2010–2012, 438t; estimates of employees with health insurance coverage, 425f; evaluating insurer performance prior to 2010 in, 442–44; evaluating insurer performance 2010 and after in, 444–53; HHI for, 2010, 440f; HHI for, 2012, 441; MLRs for fully credible insurers in, 2010–2012, 451t; number of insurers selling comprehensive health insurance in, 434–35t; performance of insurers in, for health insurance, 442–53; premiums and claims in, 448f; size of, 421–25; structure of, for health insurance, 425–42; structure of, for health insurance, prior to 2010, 427–28. See also individual markets SNA. See System of National Accounts (SNA 2008) specialty drugs, 11–12; data and descriptive trends for, 286–90; institutions governing entry, manufacturing, and pricing of, 275–81; loss of patient exclusivity of, 12; policy implications of analyses of, 304–10; results of analyses, 290–304; theoretical considerations and empirical findings for entry models of, 281–86. See also generic pharmaceuticals; loss of exclusivity (LOE)
Subject Index

stroke, 4, 45
Supplemental Health Care Exhibit (SHCE), 427, 453
survival rates, 484–85. See also cancer
Sweden, practices in volume measurement of health services in, 41t
Switzerland, practices in volume measurement of health services in, 41t
symmetry grouper, 91–92; ETG, 92, 92n12
System of National Accounts (SNA 2008), 27–28; current price measures of, 28–30

Tax Identification Numbers (TINs), 15–16, 354–55; identifying physician practices with, 355–56
TAXSIM model, 20–21, 463, 463n5
TINs. See Tax Identification Numbers (TINs)
total healthcare spending, equation for, 123
triopoly period, 259–60; defined, 11
2008 System of National Accounts (SNA 2008), 27; complications in health provision measurement in, 29–30; distinction between inputs, outputs, and outcomes of, 31–33; economic significance of prices and, 28–29; volume measurement of health services and, 30–31
United Kingdom: explicit quality adjustments in, 44–45; practices in volume measurement of health services in, 41t
United States: health care spending in, 459; insurance coverage in, 188, 191f; medical care expenditures per capita in, 81; obesity rate of, 221, 221f; practices in volume measurement of health services in, 41t; spending on biomedical research by, 480–81, 481f
vasodilators, 58
volume measurement, of health services: market/nonmarket producers and, 30–31; outputs and outcomes of, 31–33; quality change and, 35–36; weights and, 33–35
weights, choice of aggregation for types of outputs and, 33–35